Scholars Central

OtherPublished 13 Jul 2016

Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials

Authors: Nishith Singh, Ravi Madan, James L Gulley

Clinical Investigation

Volume 3 · Issue 7 · Pages 651

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Immunotherapy has been recognized as a viable therapeutic approach since the regulatory approval of the autologous cell-based vaccine sipuleucel-T in 2010. Emerging preclinical evidence and early-stage clinical studies point to a potential synergy between currently available immunotherapeutic agents and standard anticancer therapies such as radiation and chemotherapy. Several other immunotherapeutic platforms, such as immune checkpoint inhibitors and DNA- and peptide-based vaccines are also in development and clinical testing. Based on the logistics of their production, these platforms are broadly categorized as patient-specific or off-the-shelf. Together, they are beginning to transform the therapeutic landscape in prostate cancer. This article reviews the rationale behind immunotherapeutic approaches in castration-resistant prostate cancer, plus the latest available clinical data.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Nishith Singh”
  • BylineArticles whose byline prints “Ravi Madan”
  • BylineArticles whose byline prints “James L Gulley”